The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Novel T-Cell Immunotherapies Market: Focus on γδ T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells & T-Cell Vaccines - Distribution by Type of T-Cell Therapy, Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes, Others), Key Players and Key Geographies (North America, Europe, Asia Pacific & Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    June 2021

  • Pages
    193

  • View Count
    1263

Example Insights

Novel-T-Cell-Immunotherapies-Market-Context Novel-T-Cell-Immunotherapies-Market-Pipeline Novel-T-Cell-Immunotherapies-Market-Distribution-by-Target-Patient-Segment
Novel-T-Cell-Immunotherapies-Market-Partnerships-and-Collaborations Novel-T-Cell-Immunotherapies-Market-Funding-and-Investments Novel-T-Cell-Immunotherapies-Market-Clinical-Research-Landscape
Novel-T-Cell-Immunotherapies-Market-List-of-Cell-Therapy-Manufacturers Novel-T-Cell-Immunotherapies-Market-Opportunity  

 

Overview

In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable type of therapeutic intervention, which is applicable to a variety of oncological and non-oncological indications. Owing to its obvious benefits, which include high target specificity, customization potential and the ability to generate immunological memory, this form of therapy has garnered significant attention among drug developers, investors and consumers, alike. In fact, several of the initial variants of T-cell based pharmacological interventions, namely those based on chimeric antigen receptors (CARs), and antigen sensitized T-cell receptors (TCRs), are already approved and available in the market. Lately, several novel types of T-cell therapies, such as γδ T-cells, Tregs, activated T-cells, virus-driven T-cells and T-cell vaccines, have demonstrated therapeutic proof-of-concept and shown promise in the early stages of clinical research, as well. Much like their predecessors, these experimental treatment paradigms are also capable of selectively eradicating diseased cells from the body and are characterized by favorable side effect profiles. At present, the novel T-cell immunotherapies pipeline features over 200 product candidates and is anticipated to grow in the foreseen future. Further, more than 35 such therapies, including Tab-cel® (Atara Biotherapeutics), CLBS03 (Caladrius Biosciences), TVI-Brain-1 (TVAX Biomedical), Viralym-M (AlloVir) and ALS001 (Coya Therapeutics), are already being evaluated in the advanced stages of development.

So far, more than 105 academic / research institutes, as well as over 50 industry players, across the world, have made notable contributions to this upcoming segment of the T-cell immunotherapies market. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade alone. It is also worth highlighting that, in the last five years, capital investments worth over USD 4 billion were made by VC firms / other strategic investors with interest in the healthcare domain. Driven by promising clinical trial data and lucrative funding, this niche, but emerging market, is poised to witness healthy growth over the next decade.

Scope of the Report

The “Novel T-Cell Immunotherapies Market: Focus on γδ T-Cells, Tregs,  Activated T-Cells, Virus-driven T-Cells and T-Cell Vaccines - Distribution by Type of T-cell Therapy (Activated T-cell, T-cell Vaccine, Treg and Virus-driven T-cell), Target Indications (Brain Tumor, Pancreatic Cancer, Breast Cancer, Lung Cancer, Nasopharyngeal Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Post-transplant Infection, Diabetes and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific and Rest of the World), Industry Trends and Global Forecast, 2021-2030” report features an extensive study of the current market landscape and the associated future potential. The report highlights efforts of both industry players and academic organizations. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of novel T-cell immunotherapies, with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.
  • An analysis of the partnerships that have been established in this domain during the period 2015-2021 (till March), covering R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and other related agreements.
  • An analysis of investments that have been made into companies which have proprietary novel T-cell based products / technologies, during period 2014 and 2021 (till March). The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing.
  • Detailed profiles of clinical stage, novel T-cell therapies (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing and recent developments.
  • A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers involved in this market.
  • Elaborate profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability. 
  • A case study on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel T-cell immunotherapies over the coming decade. The report also includes likely sales forecasts of novel T-cell immunotherapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall novel T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Peter Hoang (Chief Executive Officer, Marker Therapeutics)
  • Patrick Dougherty (Senior Vice President, Strategy, Planning and Operations, WindMIL Therapeutics)

Key Questions Answered

  • What are the prevalent R&D trends related to novel T-cell immunotherapies?
  • What are the key therapeutic areas for which novel T-cell immunotherapies have been / are being developed?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players in this market?
  • Which players have made significant investments in this domain? 
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the novel T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of novel T-cell immunotherapies, including activated T-cell, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccine and NK T-cells. It also includes information on the key considerations for developing T-cell immunotherapies.

Chapter 4 includes detailed assessment on close to 205 novel T-cell immunotherapy candidates that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to type of T-cell therapy (activated T-cells, virus driven T-cells, Tregs, γδ T-cells, T-cell vaccines and NK T-cells), phase of development (preclinical, phase I, phase I/II, phase II, phase III and marketed), therapeutic area (oncological disorders, infectious diseases, post-transplant infections, autoimmune disorders, metabolic disorders and neurological disorders), popular target indication (lung cancer, breast cancer, cytomegalovirus infection, glioblastoma, hepatocellular carcinoma, acute myeloid leukemia, ovarian cancer, type 1 diabetes mellitus, sarcoma, HIV infections and pancreatic cancer), source of T-cell (autologous and allogeneic), route of administration (intravenous, intratumoral, subcutaneous, inhalation and intramuscular), dose frequency (multiple dose, single dose and split dose), target patient segment (children, adults and seniors), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry. In addition, the chapter includes details related to novel T-cell immunotherapies developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).

Chapter 5 provides detailed profiles of clinical stage, novel T-cell therapies being evaluated in clinical stages (phase I/II or above); each profile features an overview of the therapy, current development status, key clinical trial results, dosage regimen, details related to its manufacturing information and recent developments.

Chapter 6 presents an in-depth analysis of completed, ongoing, and planned clinical studies of various novel T-cell immunotherapies, based on various relevant parameters, such as trial registration year, trial phase, trial recruitment status, study design, type of sponsor / collaborator, leading industry players (in terms of number of registered trials conducted), enrolled patient population and key geographical regions.

Chapter 7 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2015-2021 (till March). Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product development agreements, product licensing agreements, acquisitions, service agreements, manufacturing agreements and others), type of T-cell, target therapeutic area and regional distribution of the collaborations.

Chapter 8 provides details on the various investments and grants that have been awarded to players focused on the development of  novel T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place during the period 2014 to 2021 (till March), highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain. 

Chapter 9 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 10 includes brief profiles of prominent players engaged in the development of novel T-cell immunotherapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and manufacturing capability. 

Chapter 11 provides insights on regulatory T-cells, highlighting the mechanism of Tregs, key challenges associated with the production of such therapies and recent developments in the Tregs market.

Chapter 12 features an elaborate discussion on the future commercial opportunity offered by novel T-cell immunotherapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of T-cell therapy (activated T-cell, T-cell vaccine, Treg and virus-driven T-cell), [B] target indication (brain tumour, pancreatic cancer, breast cancer, lung cancer, nasopharyngeal cancer, multiple myeloma, hepatocellular carcinoma, post-transplant infection, diabetes and others), [C] key players and [D] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Peter Hoang (Chief Executive Officer, Marker Therapeutics) and Patrick Dougherty (Senior Vice President, Strategy, Planning and Operations, WindMIL Therapeutics).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. T-Cell Immunotherapies
3.2.1. Types of Novel T-Cell Immunotherapies
3.2.1.1. Fucosylated T-Cell Therapies
3.2.1.2. Gamma Delta T-Cell Therapies
3.2.1.3. PD-1 Knockout Engineered T-Cell Therapies
3.2.1.4. TAC T-Cell Therapies
3.2.1.5. T-Cell Vaccines
3.2.1.6. Treg Cell Therapies
3.2.1.7. Virus-Driven T-Cell Therapies

3.3. Key Considerations for Developing T-Cell Immunotherapies
3.4. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel T-Cell Immunotherapies: Overall Market Landscape
4.2.1. Analysis by Type of T-Cell Therapy
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Popular Target Indications
4.2.5. Analysis by Source of T-Cell
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dose Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Analysis by Type of Developer

4.3. Novel T-cell Immunotherapies: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis By Company Size
4.3.3. Analysis By Location of Headquarters
4.3.4. Key Industry Players: Analysis by Number of Pipeline Candidates
4.3.5. Key Non-Industry Players: Analysis by Number of Pipeline Candidates

5. NOVEL T-CELL IMMUNOTHERAPY PROFILES
5.1. Chapter Overview
5.2. Immuncell-LC (GC Pharma)
5.2.1. Therapy Overview
5.3. Cytovir CMV T-Cells (Kuur Therapeutics)
5.3.1. Therapy Overview

5.4. TT10: EB-VST (Tessa Therapeutics)
5.4.1. Therapy Overview
5.5. Tab-cel (tabelecleucel) (Atara Biotherapeutics)
5.5.1. Therapy Overview
5.6. Viralym-M (ALVR105) (AlloVir)
5.6.1. Therapy Overview

5.7. CLBS03 (Caladrius Biosciences)
5.7.1. Therapy Overview
5.8. TVI-Brain-1 (TVAX Biomedical)
5.8.1. Therapy Overview

5.9. ATA230 (Atara Biotherapeutics)
5.9.1. Therapy Overview
5.10. MILs (WindMIL Therapeutics)
5.10.1. Therapy Overview
5.11. Tcelna (Opexa Therapeutics)
5.11.1. Therapy Overview

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Novel T-Cell Immunotherapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Recruitment Status
6.3.5. Analysis by Study Design
6.3.6. Analysis by Type of Sponsor / Collaborator
6.3.7. Leading Industry Players: Analysis by Number of Registered Trials
6.3.8. Leading Non-Industry Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Number of Registered Trials and Geography
6.3.10. Analysis by Enrolled Patient Population and Geography
6.3.11. Analysis by Trial Recruitment Status and Geography

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Novel T-Cell Immunotherapies Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partnership and Type of T-Cell Therapy
7.3.5. Analysis by Target Therapeutic Area
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Analysis by Geography 
7.3.7.1. Region-wise Distribution
7.3.7.2. Country-wise Distribution

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Novel T-Cell Immunotherapies Market: Funding and Investment Analysis
8.3.1. Analysis by Year of Investment
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of T-Cell Therapy
8.3.5. Most Active Players: Analysis by Number of Funding Instances
8.3.6. Most Active Investors: Analysis by Number of Funding Instances
8.3.7. Analysis by Type of Investor
8.3.8. Analysis by Geography

9. CASE STUDY ON CELL THERAPY MANUFACTURING
9.1. Chapter Overview
9.2. Overview of Cell Therapy Manufacturing
9.3. Cell Therapy Manufacturing Models
9.3.1. Centralized Manufacturing Model
9.3.2. Decentralized Manufacturing Model
9.4. Scalability of Cell Therapy Manufacturing Processes
9.4.1. Scale-Up
9.4.2. Scale-Out
9.5. Types of Cell Therapy Manufacturers
9.6. Key Challenges associated with Manufacturing of Cell Therapies
9.7. Factors Affecting the Cell Therapy Manufacturing Process
9.7.1. Characterization
9.7.2. Cost of Goods
9.8. Automation of Cell Therapy Manufacturing Process
9.9. Cell Therapy Manufacturing Supply Chain
9.10. Companies with In-House Capabilities
9.11. Contract Manufacturers
9.12. Regulatory Landscape

10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Atara Biotherapeutics
10.3. AlloVir
10.4. Eureka Therapeutics
10.5. Eutilex
10.6. GammaDelta Therapeutics
10.7. NexImmune
10.8. OSE Immunotherapeutics
10.9. Tevogen Bio
10.10. WindMIL Therapeutics

11. CASE STUDY ON RECENT DEVELOPMENTS IN TREG TARGETTING THERAPIES
11.1. Chapter Overview
11.2. Treg Targeting Therapies
11.2.1. Mechanism of Action of Tregs
11.3 Recent Developments Related to Treg Targeting Therapies

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Key Assumptions and Forecast Methodology

12.4. Global Novel T-Cell Immunotherapies Market
12.4.1. Novel T-Cell Immunotherapies Market: Distribution by Type of T-Cell Therapy
12.4.2. Novel T-Cell Immunotherapies Market: Distribution by Target Indications
12.4.3. Novel T-Cell Immunotherapies Market: Distribution by Key Players
12.4.4. Novel T-Cell Immunotherapies Market: Distribution by Geography
12.5. Novel T-Cell Immunotherapies Market: Value Creation Analysis

12.6. Novel T-Cell Immunotherapies Market: Product Wise Sales Forecast
12.6.1. Cytovir CMV T-Cells (Kuur Therapeutics)
12.6.1.1. Target Patient Population
12.6.1.2. Sales Forecast
12.6.1.3. Net Present Value
12.6.1.4. Value Creation Analysis

12.6.2. Immuncell-LC (GC Pharma)
12.6.2.1. Target Patient Population
12.6.2.2. Sales Forecast
12.6.2.3. Net Present Value
12.6.2.4. Value Creation Analysis

12.6.3. TT10: EB-VST (Tessa Therapeutics)
12.6.3.1. Target Patient Population
12.6.3.2. Sales Forecast
12.6.3.3. Net Present Value
12.6.3.4. Value Creation Analysis

12.6.4. TVI-Brain-1 (TVAX Biomedical)
12.6.4.1. Target Patient Population
12.6.4.2. Sales Forecast
12.6.4.3. Net Present Value
12.6.4.4. Value Creation Analysis

12.6.5. PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital)
12.6.5.1. Target Patient Population
12.6.5.2. Sales Forecast
12.6.5.3. Net Present Value
12.6.5.4. Value Creation Analysis

12.6.6. CLBS03 (Caladrius Biosciences)
12.6.6.1. Target Patient Population
12.6.6.2. Sales Forecast
12.6.6.3. Net Present Value
12.6.6.4. Value Creation Analysis

12.6.7. ATA230 (Atara Biotherapeutics)
12.6.7.1. Target Patient Population
12.6.7.2. Sales Forecast
12.6.7.3. Net Present Value
12.6.7.4. Value Creation Analysis

12.6.8. MILs (WindMIL Therapeutics / Bristol-Myers Squibb)
12.6.8.1. Target Patient Population
12.6.8.2. Sales Forecast
12.6.8.3. Net Present Value
12.6.8.4. Value Creation Analysis

12.6.9. Cytovir ADV T-Cells (Kuur Therapeutics)
12.6.9.1. Target Patient Population
12.6.9.2. Sales Forecast
12.6.9.3. Net Present Value
12.6.9.4. Value Creation Analysis

12.6.10. TAC01-CD19 (Triumvira Immunologics)
12.6.10.1. Target Patient Population
12.6.10.2. Sales Forecast
12.6.10.3. Net Present Value
12.6.10.4. Value Creation Analysis

12.6.11. PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology)
12.6.11.1. Target Patient Population
12.6.11.2. Sales Forecast
12.6.11.3. Net Present Value
12.6.11.4. Value Creation Analysis

12.6.12. NEXI-0002 (NexImmune)
12.6.12.1. Target Patient Population
12.6.12.2. Sales Forecast
12.6.12.3. Net Present Value
12.6.12.4. Value Creation Analysis

12.6.13. ET140203 (Eureka Therapeutics)
12.6.13.1. Target Patient Population
12.6.13.2. Sales Forecast
12.6.13.3. Net Present Value
12.6.13.4. Value Creation Analysis

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Marker Biotherapeutics
14.2.1. Interview Transcript: Peter Hoang, Chief Executive Officer
14.3. WindMIL Therapeutics
14.3.1. Interview Transcript: Patrick Dougherty, Senior Vice President, Strategy, Planning and Operations

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 4.1 Novel T-Cell Immunotherapies: Distribution by Type of T-Cell Therapy
Figure 4.2 Novel T-Cell Immunotherapies: Distribution by Phase of Development`
Figure 4.3 Novel T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 4.4 Novel T-Cell Immunotherapies: Distribution by Popular Target Indications
Figure 4.5 Novel T-Cell Immunotherapies: Distribution by Source of T-Cell
Figure 4.6 Novel T-Cell Immunotherapies: Distribution by Route of Administration
Figure 4.7 Novel T-Cell Immunotherapies: Distribution by Dose Frequency
Figure 4.8 Novel T-Cell Immunotherapies: Distribution by Target Patient Segment
Figure 4.9 Novel T-Cell Immunotherapies: Distribution by Type of Therapy
Figure 4.10 Novel T-Cell Immunotherapies: Distribution by Type of Developer
Figure 4.11 Novel T-cell Immunotherapies Developers: Distribution by Year of Establishment
Figure 4.12 Novel T-cell Immunotherapies Developers: Distribution by Company Size
Figure 4.13 Novel T-cell Immunotherapies Developers: Distribution by Location of Headquarters
Figure 4.14 Key Industry Players: Distribution by Number of Pipeline Candidates
Figure 4.15 Key Non-Industry Players: Distribution by Number of Pipeline Candidates
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2021
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and TrialRecruitment Status
Figure 6.7 Clinical Trial Analysis: Distribution by Study Design
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 6.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.11 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Figure 6.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 6.13 Clinical Trial Analysis: Distribution of Trial Recruitment Status by Geography
Figure 7.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2015-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of T-Cell Therapy
Figure 7.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 7.6 Most Active Players: Distribution by Number of Partnerships
Figure 7.7 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 7.8 Partnerships and Collaborations: Distribution by Region (Country-wise)
Figure 8.1 Funding and Investment Analysis: Cumulative Distribution of Funding Instances by Year, 2014-2021
Figure 8.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2014-2021 (USD Million)
Figure 8.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 8.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 8.5 Funding and Investments Analysis: Distribution of Amount Invested by Type of T-Cell Therapy (USD Million)
Figure 8.6 Most Active Players: Distribution by Number of Funding Instances
Figure 8.7 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.8 Funding and Investment Analysis: Distribution by Type of Investor
Figure 8.9 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Figure 8.10 Funding and Investment Analysis: Distribution by Region (Country-wise)
Figure 9.1 Steps Involved in Cell Therapy Manufacturing Process
Figure 9.2 Centralized Manufacturing: Process Model
Figure 9.3 Decentralized Manufacturing: Process Model
Figure 9.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 9.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 9.6 Cell Therapies: Potency as a Critical Quality Attribute
Figure 9.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 9.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 11.1 Tregs-Cell Therapies: Mechanism of Action
Figure 12.1 Global Novel T-Cell Immunotherapies Market, 2021-2030 (USD Billion)
Figure 12.2 Novel T-Cell Immunotherapies Market: Distribution by Type of T-Cell Therapy
Figure 12.3 Novel T-Cell Immunotherapies Market: Distribution by Target Indication
Figure 12.4 Novel T-Cell Immunotherapies Market: Distribution by Key Players
Figure 12.5 Novel T-Cell Immunotherapies Market: Distribution by Geography
Figure 12.6 Cytovir CMV T-Cells (Kuur Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.7 Immuncell-LC (GC Pharma): Sales Forecast, till 2030 (USD Million)
Figure 12.8 TT10: EB-VST (Tessa Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.9 TVI-Brain-1 (TVAX Biomedical): Sales Forecast, till 2030 (USD Million)
Figure 12.10 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Sales Forecast, till 2030 (USD Million)
Figure 12.11 CLBS03 (Caladrius Biosciences): Sales Forecast, till 2030 (USD Million)
Figure 12.12 ATA230 (Atara Biotherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.13 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Sales Forecast, till 2030 (USD Million)
Figure 12.14 Cytovir ADV T-Cells (Kuur Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 12.15 TAC01-CD19 (Triumvira Immunologics): Sales Forecast, till 2030 (USD Million)
Figure 12.16 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Sales Forecast, till 2030 (USD Million)
Figure 12.17 NEXI-0002 (NexImmune): Sales Forecast, till 2030 (USD Million)
Figure 12.18 ET140203 (Eureka Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Partnerships and Collaborations
Figure 13.4 Concluding Remarks: Funding and Investment Analysis
Figure 13.5 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Novel T-Cell Immunotherapies: Candidate Pipeline
Table 4.2 Novel T-Cell Immunotherapies: Information on Source of T-Cells, Route of Administration, Dose Frequency, Target Patient Segment and Type of Therapy
Table 4.3 Novel T-Cell Immunotherapies: List of Developers
Table 5.1 Novel T-Cell Immunotherapies: List of Therapies Profiled
Table 5.2 Therapy Profile: Immunecell-LC (GC Pharma)
Table 5.3 Therapy Profile: Cytovir CMV T-Cells (Kuur Therapeutics)
Table 5.4 Therapy Profile: TT10: EB-VST (Tessa Therapeutics)
Table 5.5 Therapy Profile: Tab-cel (tabelecleucel) (Atara Biotherapeutics)
Table 5.6 Therapy Profile: Viralym-M (ALVR105) (AlloVir)
Table 5.7 Therapy Profile: CLBS03 (Caladrius Biosciences)
Table 5.8 Therapy Profile: TVI-Brain-1 (TVAX Biomedical)
Table 5.9 Therapy Profile: ATA230 (Atara Biotherapeutics)
Table 5.10 Therapy Profile: MILs (WindMIL Therapeutics)
Table 5.11 Therapy Profile: Tcelna (Opexa Therapeutics)
Table 7.1 Novel T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2015-2021
Table 8.1 Novel T-Cell Immunotherapies: Funding and Investments, 2014-2021
Table 8.2 Novel T-Cell Immunotherapies: Summary of Investments
Table 10.1 Novel T-Cell Immunotherapy Developers: List of Companies Profiled
Table 10.2 Atara Biotherapeutics: Company Profile
Table 10.3 AlloVir: Company Profile
Table 10.4 Eureka Therapeutics: Company Profile
Table 10.5 Eutilex: Company Profile
Table 10.6 GammaDelta Therapeutics: Company Profile
Table 10.7 NexImmune: Company Profile
Table 10.8 OSE Immunotherapeutics: Company Profile
Table 10.9 Tevogen Bio: Company Profile
Table 10.10 WindMIL Therapeutics: Company Profile
Table 11.1 Treg Targeting Therapies: Candidate Pipeline
Table 11.2 Treg Targeting Therapies: Recent Developments
Table 12.1 Market Forecast of Novel T-Cell Immunotherapies: List of Molecules
Table 12.2 Cytovir CMV T-Cells (Kuur Therapeutics): Net Present Value (USD Million)
Table 12.3 Cytovir CMV T-Cells (Kuur Therapeutics): Value Creation Analysis (USD Million)
Table 12.4 Immuncell-LC (GC Pharma): Net Present Value (USD Million)
Table 12.5 Immuncell-LC (GC Pharma): Value Creation Analysis (USD Million)
Table 12.6 TT10: EB-VST (Tessa Therapeutics): Net Present Value (USD Million)
Table 12.7 TT10: EB-VST (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 12.8 TVI-Brain-1 (TVAX Biomedical): Net Present Value (USD Million)
Table 12.9 TVI-Brain-1 (TVAX Biomedical): Value Creation Analysis (USD Million)
Table 12.10 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Net Present Value (USD Million)
Table 12.11 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Value Creation Analysis (USD Million)
Table 12.12 CLBS03 (Caladrius Biosciences): Net Present Value (USD Million)
Table 12.13 CLBS03 (Caladrius Biosciences): Value Creation Analysis (USD Million)
Table 12.14 ATA230 (Atara Biotherapeutics): Net Present Value (USD Million)
Table 12.15 ATA230 (Atara Biotherapeutics): Value Creation Analysis (USD Million)
Table 12.16 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Net Present Value (USD Million)
Table 12.17 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 12.18 Cytovir ADV T-Cells (Kuur Therapeutics): Net Present Value (USD Million)
Table 12.19 Cytovir ADV T-Cells (Kuur Therapeutics): Value Creation Analysis (USD Million)
Table 12.20 TAC01-CD19 (Triumvira Immunologics): Net Present Value (USD Million)
Table 12.21 TAC01-CD19 (Triumvira Immunologics): Value Creation Analysis (USD Million)
Table 12.22 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 12.23 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 12.24 NEXI-0002 (NexImmune): Net Present Value (USD Million)
Table 12.25 NEXI-0002 (NexImmune): Value Creation Analysis (USD Million)
Table 12.26 ET140203 (Eureka Therapeutics): Net Present Value (USDMillion)
Table 12.27 ET140203 (Eureka Therapeutics): Value Creation Analysis(USD Million)
Table 14.1 Marker Biotherapeutics: Company Snapshot
Table 14.2 WindMIL Therapeutics: Company Snapshot
Table 15.1 Novel T-Cell Immunotherapies: Distribution by Type of T-cell Therapy
Table 15.2 Novel T-Cell Immunotherapies: Distribution by Phase of Development`
Table 15.3 Novel T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 15.4 Novel T-Cell Immunotherapies: Distribution by Popular Target Indications
Table 15.5 Novel T-Cell Immunotherapies: Distribution by Source of T-Cell
Table 15.6 Novel T-Cell Immunotherapies: Distribution by Route of Administration
Table 15.7 Novel T-Cell Immunotherapies: Distribution by Dose Frequency
Table 15.8 Novel T-Cell Immunotherapies: Distribution by Target Patient Segment
Table 15.9 Novel T-Cell Immunotherapies: Distribution by Type of Therapy
Table 15.10 Novel T-Cell Immunotherapies: Distribution by Type of Developer
Table 15.11 Novel T-cell Immunotherapies Developers: Distribution by Year of Establishment
Table 15.12 Novel T-cell Immunotherapies Developers: Distribution by Company Size
Table 15.13 Novel T-cell Immunotherapies Developers: Distribution by Location of Headquarters
Table 15.14 Key Industry Players: Distribution by Number of Pipeline Candidates
Table 15.15 Key Non-Industry Players: Distribution by Number of Pipeline Candidates
Table 15.16 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2021
Table 15.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 15.18 Clinical Trial Analysis: Distribution by Trial Phase
Table 15.19 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 15.20 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and TrialRecruitment Status 
Table 15.21 Clinical Trial Analysis: Distribution by Study Design
Table 15.22 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 15.23 Leading Industry Players: Distribution by Number of Registered Trials
Table 15.24 Clinical Trial Analysis: Distribution of Number of Registered Trials by Geography
Table 15.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 15.26 Clinical Trial Analysis: Distribution of Trial Recruitment Status by Geography
Table 15.27 Partnerships and Collaborations: Cumulative Distribution by Year, 2015-2021
Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.30 Partnerships and Collaborations: Distribution by Type of Partnership and Type of T-Cell Therapy
Table 15.31 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 15.32 Most Active Players: Distribution by Number of Partnerships
Table 15.33 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Table 15.34 Partnerships and Collaborations: Distribution by Region (Country-wise)
Table 15.35 Funding and Investment Analysis: Cumulative Distribution of Funding Instances by Year, 2014-2021
Table 15.36 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2014-2020 (USD Million)
Table 15.37 Funding and Investment Analysis: Distribution by Type of Funding
Table 15.38 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 15.39 Funding and Investments Analysis: Distribution by Amount Invested by Type of T-Cell Therapies (USD Million)
Table 15.40 Most Active Players: Distribution by Number of Funding Instances
Table 15.41 Most Active Investors: Distribution by Number of Funding Instances
Table 15.42 Funding and Investment Analysis: Distribution by Type of Investor
Table 15.43 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Table 15.44 Funding and Investment Analysis: Distribution by Region (Country-wise)
Table 15.45 Global Novel T-Cell Immunotherapies Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 15.46 Novel T-Cell Immunotherapy Market: Distribution by Type of T-Cell Therapy
Table 15.47 Novel T-Cell Immunotherapy Market: Distribution by Target Indications
Table 15.48 Novel T-Cell Immunotherapy Market: Distribution by Key Players
Table 15.49 Novel T-Cell Immunotherapy Market: Distribution by Geography
Table 15.50 Cytovir CMV T-Cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030: (USD Million)
Table 15.51 Immuncell-LC (GC Pharma): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.52 TT10: EB-VST (Tessa Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.53 TVI-Brain-1 (TVAX Biomedical): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.54 PD-1 Knockout Engineered T-Cells (Chengdu MedGenCell / Anhui Province Hospital): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.55 CLBS03 (Caladrius Biosciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.56 ATA230 (Atara Biotherapeutics): Sales Forecast, Conservative, Base and OptimisticScenarios, till 2030 (USD Million)
Table 15.57 MILs (WindMIL Therapeutics / Bristol-Myers Squibb): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.58 Cytovir ADV T-Cells (Kuur Therapeutics): Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 15.59 TAC01-CD19 (Triumvira Immunologics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.60 PD-1 Knockout T Cells (Guangzhou Anjie Biomedical Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.61 NEXI-0002 (NexImmune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 15.62 ET140203 (Eureka Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)

List of Companies

The following companies and organizations are mentioned in the report.

 

  1. 8VC
  2. Abingworth
  3. Acer Therapeutics
  4. Acorn Pacific Ventures
  5. Adaptate Biotherapeutics
  6. Agency for Science, Technology and Research (A*STAR)
  7. AgenTus Therapeutics
  8. Agenus
  9. Alexandria Venture Investments
  10. Allele Capital Partners
  11. AlloVir
  12. Andalusian Public Foundation for Health Research Management of Seville (FISEVI)
  13. Anhui Kedgene Biotechnology
  14. Anhui Provincial Hospital 
  15. ARCH Venture Partners
  16. ArrowMark Partners
  17. ARSEP Foundation
  18. Assistance Publique – Hôpitaux de Paris (AP-HP)
  19. Atara Biotherapeutics
  20. Austin Health
  21. Autoimmunity Centers of Excellence
  22. Barer & Son Capital
  23. Bayer
  24. Baylor College of Medicine
  25. BB Pureos Bioventures
  26. Beijing 302 Hospital
  27. Beijing Cancer Hospital
  28. Beijing Doing Biomedical Technology
  29. Beijing GD Initiative Cell Therapy Technology
  30. Beijing Genomics Institute
  31. Beijing Mabworks Biotech
  32. Beijing Tongren Hospital
  33. Beijing Youan Hospital
  34. Bellicum Pharmaceuticals
  35. Benaroya Research Institute at Virginia Mason (BRI)
  36. Besançon University Hospital
  37. Beth Israel Deaconess Medical Center
  38. Betta Pharmaceuticals
  39. BHT Lifescience Australia
  40. Bill and Melinda Gates Foundation
  41. BioCentriq
  42. Bios Partners
  43. Biox Biosciences
  44. Blood and Tissue Bank
  45. Bloom Burton
  46. bluebird bio
  47. Bpifrance 
  48. Brigham and Women's Hospital
  49. Bristol Myers Squibb
  50. British Society for Haematology
  51. Bordeaux University Hospital Center (CHU)
  52. Boston Children's Hospital
  53. Cairo University
  54. Caladrius Biosciences
  55. California Institute for Regenerative Medicine (CIRM)
  56. Cambridge University Hospitals NHS Foundation Trust
  57. Cancer Prevention Research Institute of Texas
  58. Cancer Research Institute
  59. Cancer Research Technology
  60. Case Western Reserve University
  61. Celldex Therapeutics
  62. Cell Medica
  63. Celgene
  64. Cellenkos
  65. Center for Cell and Gene Therapy
  66. Center for Clinical and Translational Sciences (CCTS)
  67. Centre for Commercialisation of Cancer Immunotherapy (C3i)
  68. Central Hospital, Nancy, France
  69. Central South University
  70. Charite – Universitatsmedizin Berlin
  71. Changi General Hospital (CGH)
  72. Chengdu MedGenCell
  73. Children's Hospital Los Angeles
  74. Children's Hospital of Philadelphia
  75. Children's National Research Institute (CNRI)
  76. Children's Oncology Group
  77. Children's Research Institute
  78. Chinese Academy of Medical Sciences
  79. Chinese PLA General Hospital (CPGH)
  80. Cincinnati Children's Hospital Medical Center
  81. City of Hope 
  82. Clinical Research Malaysia (CRM)
  83. Cognate BioServices
  84. Columbia University
  85. Coya Therapeutics
  86. CRISPR Therapeutics
  87. Cryoport 
  88. CytoMed Therapeutics
  89. Dana-Farber Cancer Institute
  90. DCVC Management
  91. Department of Health Valencia La Fe
  92. Diabetes Research Institute Foundation Canada (DRIFCan)
  93. DS Asset Management
  94. Duke-NUS Medical School
  95. Duke University
  96. Dutch Cancer Society
  97. EcoR1 Capital
  98. EDBI
  99. Emerson Collective
  100. Emmes
  101. Erciyes University
  102. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  103. Euchloe Bio (acquired by Tessa Therapeutics)
  104. Eureka Therapeutics
  105. European Commission
  106. Eutilex
  107. F2 Ventures
  108. Faculty of Medicine, University of Indonesia (FKUI)
  109. Fate Therapeutics
  110. Ferring Pharmaceuticals
  111. Fidelity Management and Research
  112. Fondazione IRCCS Policlinico San Matteo
  113. Fred Hutchinson Cancer Research Center
  114. Friedrich-Alexander University Erlangan-Nuremberg (FAU)
  115. French Blood Establishment (EFS)
  116. Friedreich’s Ataxia Research Alliance (FARA)
  117. Fuda Cancer Hospital
  118. GammaCell Bio-Technologies
  119. GammaDelta Therapeutics
  120. GC Pharma
  121. GentiBio
  122. Ghent University Hospital 
  123. Gilde Healthcare
  124. Gilead Sciences
  125. GlaxoSmithKline
  126. G.N. Tech Venture
  127. GP Capital
  128. Guangdong Xiangxue Precision Medical Technology
  129. Guangzhou Anjie Biomedical Technology
  130. Guy's and St Thomas' NHS Foundation Trust
  131. Hackensack Meridian Health
  132. Hangzhou Cancer Hospital
  133. Hannover Medical School
  134. Harbin Medical University
  135. Harris Health System (formerly known as the Harris County Hospital District)
  136. Heidelberg University Hospital
  137. Heliconia Capital Management 
  138. HengRui YuanZheng Bio-Technology
  139. Heritas Capital
  140. H. Lee Moffitt Cancer Center and Research Institute
  141. HMP Partners
  142. Hoxworth Blood Center
  143. Hunan Zhaotai Yongren Medical Innovation
  144. Icahn School of Medicine at Mount Sinai
  145. ILTOO Pharma
  146. Immune Tolerance Network
  147. Immunocore
  148. Imperial College London
  149. InnoCare Pharma
  150. International Multidisciplinary Research Foundation (IMRF)
  151. IN8bio
  152. Incyte
  153. Innovate UK
  154. Inserm
  155. Institute of Hematology and Blood Diseases Hospital
  156. Instituto de Investigación Sanitaria Valdecilla (IDIVAL)
  157. Intrexon
  158. IRCCS Company Hospital- University of Bologna
  159. ITOCHU
  160. Janssen Biotech
  161. JDRF T1D Fund 
  162. Jinan University
  163. Johns Hopkins University
  164. Jonsson Comprehensive Cancer Center
  165. Juvenile Diabetes Research Foundation (JDRF)
  166. Kaiser Permanente 
  167. Karst Peak Capital
  168. King’s College London
  169. KK Women's and Children's Hospital
  170. Knight Therapeutics
  171. Kolon Investment
  172. Kuur Therapeutics
  173. Kyverna Therapeutics
  174. LAVA Therapeutics
  175. Leukemia and Lymphoma Society
  176. Liana's Dream Foundation
  177. Lifeforce Capital
  178. Lightspeed Venture Partners
  179. Lilly Asia Ventures
  180. Lonza
  181. Ludwig Institute for Cancer Research
  182. Lupus Ventures
  183. Lyell Immunopharma
  184. Lymphact (acquired by GammaDelta Therapeutics)
  185. Mahidol University
  186. Maisonneuve-Rosemont Hospital
  187. Massachusetts General Hospital
  188. Matrix Capital Management
  189. Mayo Clinic
  190. MD Anderson Cancer Center
  191. Medical College of Wisconsin
  192. Medical Research Council
  193. Medical University of Lublin
  194. Medical University of Vienna
  195. Memorial Sloan Kettering Cancer Center
  196. Merck Sharp & Dohme
  197. Methodist Hospitals
  198. MIGAL Galilee Research Institute
  199. Miltenyi Biomedicine
  200. Miltenyi Biotec
  201. Ministry of Science and Higher Education, Poland
  202. MMH Institute for Transfusion Medicine
  203. Mogrify
  204. Mount Sinai Hospital
  205. MPM Capital
  206. MRL Ventures Fund
  207. Mubadala Investment Company
  208. Multiple Myeloma Research Foundation (MMRF)
  209. Nanjing Drum Tower Hospital (Nanjing Gulou Yi Yuan)
  210. Nanjing Medical University
  211. Nantes University Hospital
  212. National Cancer Institute
  213. National Center for Tumor Diseases (NCT)
  214. National Health and Medical Research Council (NHMRC)
  215. National Heart, Lung, and Blood Institute (NHLBI)
  216. National Institute for Health Research (NIHR)
  217. National Institute of Allergy and Infectious Diseases (NIAID)
  218. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  219. National Institutes of Health (NIH)
  220. National Marrow Donor Program
  221. National University Hospital (NUH)
  222. Nationwide Children's Hospital
  223. ND Capital
  224. Nice University Hospital
  225. Neon Therapeutics
  226. New Enterprise Associates
  227. New York Medical College
  228. NexImmune
  229. Northpond Ventures
  230. Northwestern University
  231. Nova Immunotherapeutics 
  232. Novartis Venture Fund
  233. Novo Ventures
  234. NYU Langone Health
  235. Oceanpine Capital
  236. Octagon Capital
  237. Ohio University
  238. Oncovir
  239. Opexa Therapeutics
  240. OrbiMed
  241. Orca Bio
  242. Ospedale San Raffaele
  243. OU Health Stephenson Cancer Center
  244. PapiVax Biotech
  245. Pancreatic Cancer Action Network
  246. University Paris-Est Creteil Val de Marne (formerly known as the Université Paris XII)
  247. Parker Institute for Cancer Immunotherapy
  248. Peking University People's Hospital
  249. Penn State Health Milton S. Hershey Medical Center
  250. Peter MacCallum Cancer Institute
  251. PersonGen BioTherapeutics (Suzhou)
  252. Pfizer
  253. Piedmont Capital Partners
  254. Pierce Phillips Charity
  255. Pierre and Marie Curie University (UPMC)
  256. Prometheus Laboratories
  257. Providence Cancer Institute
  258. Qiming Venture Partners
  259. QIMR Berghofer Medical Research Institute
  260. Quell Therapeutics
  261. Queensland Institute of Medical Research (QIMR) Berghofer
  262. RA Capital Management
  263. Radboud University
  264. Redmile Group
  265. Rho Federal Systems Division
  266. Roswell Park Cancer Institute
  267. Samsara BioCapital
  268. Sanford Health
  269. Sangamo Therapeutics
  270. Sanofi Ventures
  271. Seattle Children’s Research Institute
  272. Second Xiangya Hospital of Central South University
  273. Sengkang General Hospital
  274. Seoul National University Hospital (SNUH)
  275. Shanghai General Hospital
  276. Shanghai Houchao Biotechnology 
  277. Shanghai iCELL Biotechnology
  278. Shanghai Jiao Tong University School of Medicine
  279. Shanghai Public Health Clinical Center
  280. Sheffield Institute for Translational Neuroscience
  281. Shenzhen Geno-Immune Medical Institute
  282. Shenzhen Hornetcorn Biotechnology
  283. Shenzhen Second People's Hospital
  284. Shenzhen Third People's Hospital
  285. Sichuan University
  286. Singapore General Hospital
  287. Siriraj Hospital
  288. Sixth Affiliated Hospital
  289. SNU Bio Angel
  290. SoftBank Vision Fund
  291. Solving Kids' Cancer
  292. Sonoma Biotherapeutics
  293. Specialized Medical Services-oncology
  294. SR One
  295. St. George's Hospital
  296. St. Jude Children’s Research Hospital
  297. Stanford University
  298. Sun Yat-sen University
  299. Surveyor Capital
  300. Syncona
  301. SYZ Cell Therapy
  302. Takeda Pharmaceutical
  303. Targazyme
  304. Temasek
  305. Tessa Therapeutics
  306. Tevogen Bio
  307. The Atlantic Philanthropies
  308. The Egyptian IVF-ET Center
  309. The First Affiliated Hospital of Xi'an Jiaotong University
  310. The First Affiliated Hospital of Guangdong Pharmaceutical University
  311. The First Affiliated Hospital of Guangzhou Medical University
  312. The First Affiliated Hospital of Soochow University
  313. The Francis Crick Institute
  314. The First People's Hospital of Lianyungang
  315. The Invus Group
  316. The University of Alabama at Birmingham
  317. The University of Kansas Medical Center
  318. The University of Utah
  319. The V Foundation for Cancer Research
  320. Tianjin Medical University Cancer Institute and Hospital
  321. TRACT Therapeutics
  322. Triumvira Immunologics
  323. TVAX Biomedical 
  324. TxCell 
  325. UBS Oncology Impact Fund
  326. UCL Technology Fund
  327. University College London (UCL)
  328. University Health Network, Toronto
  329. University Hospital Cologne
  330. University Hospital of Saint-Étienne
  331. University Hospital of Montpellier
  332. University Hospital of Würzburg
  333. University Hospital Regensburg
  334. University of Alabama
  335. University of Alberta
  336. University of Arkansas
  337. University of California
  338. University of Cambridge
  339. University of Cincinnati
  340. University of Colorado
  341. University of Kansas Medical Center
  342. University of Kentucky
  343. University of Liege
  344. University of Maryland
  345. University of Miami
  346. University of Michigan
  347. University of Minnesota Medical Center
  348. University of Pennsylvania
  349. University of Perugia
  350. University of Pittsburgh
  351. University of Regensburg
  352. University of Sydney
  353. University of Technology Sydney
  354. University of Texas
  355. University of Wisconsin
  356. University of Wisconsin Carbone Cancer Center (UWCCC)
  357. University of Wisconsin School of Medicine and Public Health
  358. UW Health
  359. Vall d'Hebron Institute of Oncology
  360. V Foundation for Cancer Research
  361. Versant Ventures
  362. Vertex Ventures
  363. Veterans Affairs (VA) Office of Research and Development
  364. Vida Ventures
  365. ViGenCell
  366. Vineti
  367. Vir Biotechnology
  368. Viva Biotech
  369. VT BIO
  370. Vyriad
  371. Washington University School of Medicine
  372. Wellcome Trust
  373. Westlake Village BioPartners
  374. WindMIL Therapeutics
  375. Wuhan Union Hospital
  376. Xiangxue Life Science Research Center
  377. Xiangxue Pharmaceutical
  378. Yale University
  379. Ysios Capital
  380. Zhejiang Huahai Pharmaceutical
  381. Zhujiang Hospital of Southern Medical University

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com